VivoSeq
Other

Strongyloidiasis

4

Pipeline Programs↗

0

Active Trials↗

3

Companies Involved↗

Strongyloidiasis is an early-stage landscape with 4 programs across 3 companies. The most active players are Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), GSK, Medicines Development for Global Health. 1 therapy is approved with 2 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

24/100

Pipeline Velocity

0/100

Mech. Concentration

100/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

C

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

1 program

Phase 3GSK logo

GSK

1 program

Phase 3M

Medicines Development for Global Health

1 program

Approved

Pipeline

Programs by Phase

Analysis

Trial Status

4

clinical trials

Completed3 · 75%
Unknown status1 · 25%

Clinical Trials

Trial Activity

Management of Soil-transmitted Helminthiasis and Strongyloidiasis
Unknown status·UUniversidad Nacional de Salta·N/A·NCT01308268·2,000 enrolled
Ivermectin Versus Albendazole for Chronic Strongyloidiasis
Completed·MMahidol University·Phase 3·NCT00765024·90 enrolled
Multiple Versus Single Dose of Ivermectin for the Treatment of Strongyloidiasis
Completed·CCentro per le Malattie Tropicali·Phase 3·NCT01570504·312 enrolled
Efficacy and Safety of Emodepside in Adults Infected With Strongyloidiasis Stercoralis
Completed·SSwiss Tropical & Public Health Institute·Phase 2·NCT06373835·202 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)